IEC issues corporate update on Kubby Cryogenics
TEMECULA, Calif., Oct. 30, 2017 (GLOBE NEWSWIRE) -- International Endeavors Corporation (OTC:IDVV) ("IEC"
today announced updates on KUBBY Cryogenics, Inc., subsidiary partner of IEC, and biomedical cannabis research and development firm.
Kubby Cryogenics manufacturing division produces a unique biomedicine from the raw cannabis plant. This new class of medicine, the Kubby Cryogenics method, is the company’s own proprietary method capturing the vitality of the raw plant in its extraction process. This small batch, apothecary approach captures the live resins that have medical benefits for a number of ailments, including: cancer, inflammatory disease, epilepsy, brain injury, autism, Alzheimer’s, and more.
Currently research being done focuses on the medical value in specific strains that may be used in the company’s proprietary Cryogenic process, a broad-spectrum therapy. Kubby Cryogenics is working with genetic partners to secure several medicinal strains to patent for this use. Most people of all ages can potentially use Kubby Cryogenics because it’s naturally a non-psychoactive product.
“Our Cryogenic process appears to trigger the production of Adult Stem Cells, based on independent research on the Endocannabinoid system and the entourage effect,” said Steve Kubby, CEO and President of Kubby Cryogenics. According to a recent peer reviewed study, the endocannabinoid system directs cell fate specification of Neural Stem Cells in the Central Nervous System, which can lead to new cell generation in the brain and the periphery systems. (https://www.ncbi.nlm.nih.gov/pubmed/24076098 and 24256257)
Kubby Cryogenics is in the process of gathering information from its research and testimonials of patients. We plan to develop a website shortly that will focus on Kubby Cryogenics and its efforts.
Cryogenics Medical Uses Cancer, Fibromyalgia, Arthritis, High Blood Pressure, Epilepsy, Brain Injury, Stroke, Inflammation, and PTSD.
Mr. Steve Kubby Bio Steven Wynn "Steve" Kubby played a key role in the passage of California Proposition 215, a ballot initiative passed in 1996 to legalize medical marijuana. He is a well-known cancer patient of 36 years, who benefits his recovery through the use of non-psychoactive Cryogenics, a raw cannabis extract. Steve Kubby was formally Chairman and CEO of Cannabis Sativa Inc., traded under the symbol CBDS, and has authored 2 books on drug policy reform. Mr. Kubby's distinguished political career includes runs for Governor of California in 1998, and the 2008 Presidential primary race under the libertarian ticket.
About International Endeavors Corporation International Endeavors Corporation is a company focused on biomedical uses of non-psychoactive cannabis based products for the treatment of a wide variety of illnesses. Through a unique patent pending Cryogenic process, the Company can process different unique medical grade cannabis strains that are genetically profiled to treating specific diseases. www.internationalendeavorscorp.com
Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. International Endeavors Corporation (IDVV) is under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT INFORMATION
Contact: Nobia Kubby Chief Operations Officer Phone: 831-383-2141 Email: Nobia@kubbyinc.com
TEMECULA, Calif., Oct. 30, 2017 (GLOBE NEWSWIRE) -- International Endeavors Corporation (OTC:IDVV) ("IEC"
today announced updates on KUBBY Cryogenics, Inc., subsidiary partner of IEC, and biomedical cannabis research and development firm. Kubby Cryogenics manufacturing division produces a unique biomedicine from the raw cannabis plant. This new class of medicine, the Kubby Cryogenics method, is the company’s own proprietary method capturing the vitality of the raw plant in its extraction process. This small batch, apothecary approach captures the live resins that have medical benefits for a number of ailments, including: cancer, inflammatory disease, epilepsy, brain injury, autism, Alzheimer’s, and more.
Currently research being done focuses on the medical value in specific strains that may be used in the company’s proprietary Cryogenic process, a broad-spectrum therapy. Kubby Cryogenics is working with genetic partners to secure several medicinal strains to patent for this use. Most people of all ages can potentially use Kubby Cryogenics because it’s naturally a non-psychoactive product.
“Our Cryogenic process appears to trigger the production of Adult Stem Cells, based on independent research on the Endocannabinoid system and the entourage effect,” said Steve Kubby, CEO and President of Kubby Cryogenics. According to a recent peer reviewed study, the endocannabinoid system directs cell fate specification of Neural Stem Cells in the Central Nervous System, which can lead to new cell generation in the brain and the periphery systems. (https://www.ncbi.nlm.nih.gov/pubmed/24076098 and 24256257)
Kubby Cryogenics is in the process of gathering information from its research and testimonials of patients. We plan to develop a website shortly that will focus on Kubby Cryogenics and its efforts.
Cryogenics Medical Uses Cancer, Fibromyalgia, Arthritis, High Blood Pressure, Epilepsy, Brain Injury, Stroke, Inflammation, and PTSD.
Mr. Steve Kubby Bio Steven Wynn "Steve" Kubby played a key role in the passage of California Proposition 215, a ballot initiative passed in 1996 to legalize medical marijuana. He is a well-known cancer patient of 36 years, who benefits his recovery through the use of non-psychoactive Cryogenics, a raw cannabis extract. Steve Kubby was formally Chairman and CEO of Cannabis Sativa Inc., traded under the symbol CBDS, and has authored 2 books on drug policy reform. Mr. Kubby's distinguished political career includes runs for Governor of California in 1998, and the 2008 Presidential primary race under the libertarian ticket.
About International Endeavors Corporation International Endeavors Corporation is a company focused on biomedical uses of non-psychoactive cannabis based products for the treatment of a wide variety of illnesses. Through a unique patent pending Cryogenic process, the Company can process different unique medical grade cannabis strains that are genetically profiled to treating specific diseases. www.internationalendeavorscorp.com
Forward-Looking Statements are included within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements and involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. International Endeavors Corporation (IDVV) is under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
CONTACT INFORMATION
Contact: Nobia Kubby Chief Operations Officer Phone: 831-383-2141 Email: Nobia@kubbyinc.com
